Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Bright Minds Biosciences Inc. (DRUG : NSDQ)

• Company Description    Bright Minds Biosciences is a biotechnology company. It focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain. Bright Minds Biosciences is based in VANCOUVER, British Columbia. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $78.04 Daily Weekly Monthly 20 Day Moving Average: 154,349 shares Shares Outstanding: 7.79 (millions) Market Capitalization: $607.60 (millions) Beta: -6.15 52 Week High: $97.75 52 Week Low: $23.18 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.64% 7.82% 12 Week 27.08% 25.03% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 400 N ABERDEEN ST SUITE 900 - CHICAGO,IL 60642 USA ph: 64-7407-2515 fax: - lwilson@insitecony.com https://brightmindsbio.com

• General Corporate Information    Officers Ian McDonald - Chief Executive Officer and Director Alex Vasilkevich - Chief Operating Officer Ryan Cheung - Chief Financial Officer Jeremy Fryzuk - Director Nils Bottler - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 10919W405 SIC: 2834 Fiscal Year Fiscal Year End: September Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/12/26 Share - Related Items Shares Outstanding: 7.79 Most Recent Split Date: 7.00 (0.20:1) Beta: -6.15 Market Capitalization: $607.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.15 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.22 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 9.37 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -241.67% vs. Previous Quarter: 22.64% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -19.92 06/30/25 - -20.96 ROA 12/31/25 - - 09/30/25 - -19.57 06/30/25 - -20.66 Current Ratio 12/31/25 - - 09/30/25 - 36.09 06/30/25 - 86.64 Quick Ratio 12/31/25 - - 09/30/25 - 36.09 06/30/25 - 86.64 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 8.33 06/30/25 - 5.32 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.05 06/30/25 - 0.12

Powered by Zacks Investment Research ©